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Abstract: Activation of an aberrant glycosylation pathway in cancer cells can lead to expression of
the onco-foetal sialyl-Tn (sTn) antigen. STn is a truncated O-glycan containing a sialic acid α-2,6
linked to GalNAc α-O-Ser/Thr and is associated with an adverse outcome and poor prognosis
in cancer patients. The biosynthesis of the sTn antigen has been linked to the expression of the
sialytransferase ST6GalNAc1, and also to mutations in and loss of heterozygosity of the COSMC
gene. sTn neo- or over-expression occurs in many types of epithelial cancer including gastric, colon,
breast, lung, oesophageal, prostate and endometrial cancer. sTn is believed to be carried by a
variety of glycoproteins and may influence protein function and be involved in tumour development.
This review discusses how the role of sTn in cancer development and tumour cell invasiveness
might be organ specific and occur through different mechanisms depending on each cancer type or
subtype. As the sTn-antigen is expressed early in carcinogenesis targeting sTn in cancer may enable
the targeting of tumours from the earliest stage.
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1. Introduction
Aberrant Glycosylation can play an important role in key fundamental processes occurring in
cancer and changes in O-glycosylation are frequently observed [1]. O-glycosylation of proteins is a
diverse and abundant form of post-translational modification that occurs in the Golgi apparatus
and depends on the sequential action of several glycosylation enzymes. The biosynthesis of
O-glycans is initiated by a family of up to 20 GalNAc-transferases that transfer N-Acetylgalactosamine
(GalNAc) to serine threonine residues on proteins to produce the Tn antigen. The Tn antigen is
then further branched and capped in subsequent processing steps by a large number of different
glycosyltransferases. In normal cells, O-glycosylation proceeds to mature elongated and branched
O-glycans, which are frequently modified with sialic acid. An increase in global sialylation has been
closely associated with cancer and can play a fundamental role in cell adhesion, cellular recognition
and cell signalling [1,2].
The pattern of glycans expressed in a cell depends on the glycosyltransferases expressed, their
substrate specificity, and localisation. In cancer cells the processing of O-glycans to mature branched
structures is often disrupted, and they express only early biosynthetic intermediates [3,4]. The sialyl-Tn
antigen (Neu5Acα2-6GalNAcα-O-Ser/Thr), known as sTn, is a truncated O-glycan containing a sialic
acid α-2,6 linked to GalNAc α-O-Serine/Threonine (Ser/Thr). sTn is expressed by more than 80%
of human carcinomas and is linked to poor prognosis in cancer patients. The sTn antigen was
first discovered as a cancer marker >30 years ago. Early studies identified the sTn as a marker for
diagnosis and prognosis in cancer, and later work focused on using sTn as a potential therapeutic target.
sTn neo- or over-expression has been described in many types of epithelial cancer including: gastric [5],
colon [6], breast [7,8], lung [9], oesophageal [10], pancreatic [11], prostate [12,13], bladder [14],
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and endometrial cancer [15]. Studies suggest that sTn expression has primarily been detected at
the apical or luminal surface of tissue and tends to occur in early carcinogenesis [16].
2. Synthesis of the Sialyl-Tn (sTn) Antigen
The expression of truncated O-glycans in cancer has been proposed to result from altered
expression of glycosyltransferases [17], hypermethylation or mutations in COSMC (core 1
β3-Gal-T-specific molecular chaperone) [18,19], mis-localisation of GalNAc-transferases from the Golgi
to the endoplasmic reticulum (ER) [20], and fluctuations in pH levels [21]. Specifically, biosynthesis of
the sTn antigen has been linked to the expression of the sialytransferase ST6GalNAc1, and to mutations
in and loss of heterozygosity of the COSMC gene (Figure 1). The biosynthesis of sTn can be mediated
in vitro by the specific sialyltransferases ST6GalNAc1 and ST6GalNAc2 [22,23]. However, in a cellular
context only ST6GalNAc1 is able to synthesise sTn [17,22], and over-expression of ST6GalNAc1 in
gastric, breast and prostate cell lines has been shown to induce expression of sTn, indicating a crucial
role for this enzyme in sTn biosynthesis [17,24–26].
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Figure 1. Biosynthesis of the Sialyl-Tn (sTn) antigen in cancer cells.
The enzyme C1Ga1T1 catalyses the common first elongation step of the Tn antigen to produce
the core 1 O-glycan structure (T antigen) a d requires t COSMC chaperone protein for correct
folding an activity [18,27–29]. Mutations in and loss of het rozygosity of the COSMC gene have
been identified in sTn positive colon and melanoma cell lines, and also in sTn positive cervical cancer
tissue [18]. Although these events are thought to be rare in breast and colon cancer [30], up to 40%
of cases of pancreatic cancer have been found to have hypermethylation of the COSMC gene, and a
corresponding increase in truncated O-glycans [19]. Increased expression of sTn in cancer may also
be enhanced by increased synthesis of the O-GalNAc precursor and decreased competition due to
reduced core-synthesis.
3. sTn Is an Onco-Foetal Antigen
Monoclonal antibodies specific to sTn have b en used to how that overall exp ession of sTn
is rare in normal compared t cancer tissues, leading t sT b ing described as an onco-foetal
antigen [16]. However, while there are some stu ies describing sTn detection in f et l organs and
amniotic fluids [7,31–33], a role for sTn in embryonic development remains to be identified. In adult
healthy tissues, low sTn expression has been detected in the salivary gland, oesophagus and stomach,
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and appears to be restricted to the upper digestive tract [7,34,35]. Expression of sTn has also been linked
to inflammatory diseases of the digestive tract and may be regulated by -interferon inflammatory
signals [36–38]. sTn is believed to be carried by a number of glycoproteins which are differentially
expressed in different cell types [16]. In mucinous cells, sTn is carried by glycoproteins such as mucins
which can be either membrane bound and secreted [39,40]. Squamous cells mainly have intensive
staining in the cytoplasm and some staining on the cell membrane [10,41]. MUC1 (mucin 1, cell surface
associated), CD44 (CD44 molecule, Indian blood group), integrin β1 and osteopontin proteins have
been identified as sTn carrier proteins [24,42–44], all of which have roles in cell adhesion, migration or
chemotaxis. It is thought that the addition of sTn to these glycoproteins may influence protein function
and play a role in specific mechanisms involved in tumour development [45].
4. sTn as a Prognostic Biomarker
Detection of serum tumour markers is a non-invasive, simple method for diagnosis and
post-surgery analysis. The sTn antigen enters serum through O-glycoprotein shedding or secretion
from tumours into the bloodstream. This requires a large amount of tumour mass, which is more
likely found in advanced cancers and is therefore associated with poor prognosis. A high level
of sTn (>38 U/mL) has been detected in the sera of patients with gastric, colorectal, pancreatic,
cervical, endometrial and ovarian cancers [15,46–53], and is associated with tumour size and
metastasis [46,47,54]. In prostate cancer, sTn is detected in up to half of all high grade tumours [12,13],
and sTn-MUC1 has been correlated with survival outcome and higher serum Prostate Specific Antigen
(PSA) levels [55]. A recent study has also linked elevated serum sTn levels to histological grade and
lymph node metastasis in endometrial cancer [15].
While sTn has been associated with decreased overall survival of patients, this may depend on
the type of cancer studied [16]. For example, in lung cancer, no link to survival was found [56], and in
prostate cancer the STGalNAc1 enzyme was found to be up-regulated in primary prostate cancer tissue
but significantly down-regulated in metastatic lesions [25]. Studies in these cancer types have been
limited, but is hoped that additional investigations will help further determine the prognostic value of
sTn in different cancer types.
5. The Role of sTn in Cancer Progression
Truncated O-glycans occur on the majority of epithelial cancers and in many pre-malignant
lesions [11,57,58]. A recent study by Radhakrishnan et al. showed that immature truncated O-glycans
can directly induce oncogenic features in cancer cells, including increased proliferation, loss of tissue
architecture, disruption of basement membrane adhesion and invasive growth [19]. In breast and
gastric cancer cell lines, sTn up-regulation is linked to increased tumour growth and metastases
in in vivo models [24,42]. Although induction of sTn inhibited the formation of stable tumour
masses in prostate cancer, potentially promoting cancer cell dissemination, there was no effect upon
metastasis [25]. Consistent with this, sTn positive ovarian cancer cells are more frequently observed at
the invasive front of tumours but less often in metastatic lesions [59,60], and breast ductal invasive
carcinomas have lower levels of sTn than primary ductal carcinomas [61]. Studies have suggested
that sTn can play a role in protecting metastatic cells in the blood stream from degradation by the
immune system [62]. Alterations in glycoprotein composition on the cell surface can induce or prevent
the recognition by lectin molecules such as selectins, siglecs and galectins, which can play a role in
cell–cell and cell–matrix interactions, and may influence cancer progression [63]. As the biosynthesis
of sTn gives rise to negative charges, sTn expression is implicated in the interaction of cells with their
surrounding environment [64]. It is likely that the sTn-antigen facilitates the release of individual
cells from the primary tumour mass by reducing cell–cell aggregation, for example by disrupting the
interaction of galectins with terminal galactose residues [65,66]. Thus, in some cases, sTn may enhance
the dissemination of cancer cells, promoting primary tumour transition, but may not improve the
settlement of metastatic cells at secondary sites [25]. Cells expressing sTn may have an improved ability
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to migrate and invade underlying tissue and eventually reach blood or lymph vessels [67]. As specific
adhesive properties are needed for successful extravasation of metastatic cells and invasion of target
tissue, one possibility is that sTn can sometimes play a transient role in cancer progression [25].
Targeting sTn carrier proteins is a potential cancer therapeutic option. It remains open whether
sTn might be carried on cancer stem cell marker proteins but as these proteins can be modified
with O-glycans this seems a likely possibility [68]. The expression of sTn is generally reported to be
heterogeneous within tumours [39,69–73] and could be regulated in the tumour via the expression of
carrier proteins. As sTn can be carried by different glycoproteins in different compartments, its role
in cancer progression may be different in different tumour types, and the effect of sTn expression on
tumour cell invasiveness might be organ specific. Together these findings suggest that the biological
function of sTn in promoting cancer development may occur through different mechanisms depending
on each cancer type or subtype. Future studies using animal models expressing sTn in multiple cancer
types and cell backgrounds will help further elucidate the role in sTn in cancer cell invasion and
metastasis in different cancers.
Immunotherapy, or using the patient’s own immune system to target cancer cells, is an attractive
approach to treat cancer, and the side-effects are mild compared with traditional therapies. Anti-tumour
antibodies could delay tumour growth by antibody dependent cytotoxicity and inhibition of function.
Since healthy adult epithelial cells do not normally expose the sTn antigen to the immune system and
bloodstream, the use of sTn as an immunisation antigen is an attractive option [16,74,75]. Clinical
studies have demonstrated that immunisation with anti-sTn vaccines can induce production of sTn
specific IgGs [76–78], and in murine models sTn vaccines have been found to induce antibody mediated
tumour protection [44]. Additionally, in early stage breast cancer, the detection of antibodies against
MUC1-sTn is associated with increased time to metastasis suggesting a protective role of anti-sTn
antibodies [79]. sTn antibodies have been detected in healthy females who did not go on to develop
cancer 25–30 years after blood sampling, suggesting a possible functional role or these antibodies in
suppressing tumour development [79].
The Theratope anti-sTn vaccine produces an anti-sTn immune response and is well tolerated
by patients with little toxicity [80–82]. In phase II clinical trials for patients with metastatic breast
cancer there was a significant improvement in survival by 12 months [80–84]. These promising results
led to a randomised, double blind phase III trial involving over 1000 women with metastatic breast
cancer, but unfortunately in this trial Theratope failed to demonstrate improved patient survival or
time to disease progression [76]. One possible explanation for the failure of the Theratope phase III
clinical trial is that the patients were not pre-evaluated for sTn expression, meaning that heterogeneous
sTn expression between patients could have masked any benefit of the vaccine [16]. A concurrent
study showed that Theratope did increase survival in a pre-stratified subset of patients who were
receiving hormonal therapy [85]. The reasons why anti-sTn immunisation seems to only be effective in
a subset of patients remain unclear but the overall results point to a relative efficiency and safety of the
Theratope vaccine.
In recent years, there has been rapid progress in antibody production methodology, including the
immortalisation of human B cells, phage display technology and high throughput screening, transgenic
mice and more recently molecular-engineered antibodies [86]. It is hoped these new technologies
may have the potential to develop novel antibodies against sTn for use in cancer treatment [86].
An immunotherapy approach targeting sTn carrier proteins may offer the possibility to target more
specific mechanisms in tumour development. For example, vaccines targeting MUC1-sTn have been
evaluated in clinical trials (Bradbury and Shepherd, 2008, Beatson et al., 2010). MUC1 is expressed
on the surface of epithelial cells where it is involved in cell adhesion and signalling (Hollingsworth
and Swanson, 2004), and can be aberrantly glycosylated with sTn (Burdick et al., 1997). It may also
be possible to create cell therapy via training dendritic cells (DCs) or T cells with sTn or sTn carrier
proteins as a tool for cancer therapy. For anti-sTn therapy to advance further it will be vital to fully
understand the role that the sTn antigen plays in the function of sTn expressing proteins and in
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overall tumour progression. Once this is achieved, it may also be possible to combine sTn with other
cancer associated antigens in order to trigger multi-antigenic responses in patients to create new
platforms for delivery of anti-tumour therapeutics based on the patient’s personal tumour profile
(Niederhafner et al., 2008, Slovin, 2007). As the sTn-antigen is expressed early in carcinogenesis in all
epithelial cancers investigated, targeting sTn in cancer may enable the targeting of tumours from the
earliest stage.
6. Future Perspectives
Many proteins with central roles in cell–cell adhesion, differentiation and development are
O-glycosylated and known to have roles in cancer [19,87]. Induction of sTn in cancer could potentially
produce global effects on O-glycosylation of proteins, and simultaneously affect multiple systems
to promote tumour formation and growth, meaning that deciphering the molecular mechanisms
underlying the role of sTn in cancer will not be straightforward. Site specific modification of
proteins with O-glycans can have profound effects on protein functions such as pro-protein processing,
modulation of ligand binding properties of receptors and regulation of cell signalling [88–90]. Future
studies determining the specific effects of sTn on specific glycoproteins will help further dissect the
role of sTn in cancer.
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